Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies

The Chimeric antigen receptor (CAR)-T cell therapy has made inroads in treating hematological malignancies. Nonetheless, there are still multiple hurdles in CAR-T cell therapy for solid tumors. Primary CAR-expressing macrophage cells (CAR-Ms) and induced pluripotent stem cells (iPSCs)-derived CAR-ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Siyu, Lei, Anhua, Wang, Xudong, Lu, Hengxing, Wang, Shuhang, Yang, Yuqi, Li, Ning, Zhang, Yi, Zhang, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139529/
https://www.ncbi.nlm.nih.gov/pubmed/35626689
http://dx.doi.org/10.3390/cells11101652
Descripción
Sumario:The Chimeric antigen receptor (CAR)-T cell therapy has made inroads in treating hematological malignancies. Nonetheless, there are still multiple hurdles in CAR-T cell therapy for solid tumors. Primary CAR-expressing macrophage cells (CAR-Ms) and induced pluripotent stem cells (iPSCs)-derived CAR-expressing macrophage cells (CAR-iMacs) have emerged as attractive alternatives in our quest for an efficient and inexpensive approach for tumor immune cell therapy. In this review, we list the current state of development of human CAR-macrophages and provide an overview of the crucial functions of human CAR-macrophages in the field of tumor immune cell therapy.

Ejemplares similares